FRANCINI, EDOARDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.876
AS - Asia 3.842
EU - Europa 3.489
SA - Sud America 1.069
AF - Africa 108
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.417
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.736
CN - Cina 1.114
RU - Federazione Russa 1.051
IT - Italia 914
SG - Singapore 885
BR - Brasile 834
VN - Vietnam 618
PL - Polonia 530
KR - Corea 390
HK - Hong Kong 357
IE - Irlanda 276
FI - Finlandia 166
BD - Bangladesh 142
AR - Argentina 118
FR - Francia 115
SE - Svezia 105
CA - Canada 82
GB - Regno Unito 80
JP - Giappone 79
ID - Indonesia 75
DE - Germania 66
DK - Danimarca 58
IN - India 58
EC - Ecuador 43
AU - Australia 31
MX - Messico 28
IQ - Iraq 26
LU - Lussemburgo 25
NG - Nigeria 25
JO - Giordania 19
CL - Cile 17
NL - Olanda 17
ZA - Sudafrica 17
ES - Italia 16
BJ - Benin 15
CO - Colombia 14
CH - Svizzera 12
PE - Perù 12
UA - Ucraina 12
MA - Marocco 11
TR - Turchia 10
PK - Pakistan 9
PY - Paraguay 9
UY - Uruguay 9
UZ - Uzbekistan 9
JM - Giamaica 8
VE - Venezuela 8
CR - Costa Rica 7
DZ - Algeria 7
EG - Egitto 7
KE - Kenya 7
TN - Tunisia 7
SA - Arabia Saudita 6
AT - Austria 5
BO - Bolivia 5
LT - Lituania 5
PH - Filippine 5
AZ - Azerbaigian 4
IL - Israele 4
KW - Kuwait 4
KZ - Kazakistan 4
LV - Lettonia 4
MY - Malesia 4
RS - Serbia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BE - Belgio 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HN - Honduras 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
CZ - Repubblica Ceca 2
GR - Grecia 2
HU - Ungheria 2
KG - Kirghizistan 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CD - Congo 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
HR - Croazia 1
HT - Haiti 1
IR - Iran 1
KH - Cambogia 1
LK - Sri Lanka 1
LY - Libia 1
MD - Moldavia 1
Totale 14.407
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.002
Singapore 683
Ashburn 575
Warsaw 526
Seoul 388
Hefei 376
Fairfield 353
Hong Kong 312
Dublin 271
Ho Chi Minh City 204
Milan 194
Woodbridge 184
Seattle 149
Beijing 140
Helsinki 138
The Dalles 128
Dallas 127
Hanoi 122
Cambridge 118
Wilmington 118
Council Bluffs 115
Los Angeles 112
Rome 106
Houston 104
San Jose 104
Altamura 96
Lawrence 96
Buffalo 93
New York 92
Lauterbourg 90
Moscow 84
Tokyo 79
São Paulo 75
Copenhagen 58
Florence 58
Princeton 51
Kent 43
Jakarta 41
Dong Ket 40
San Diego 38
Haiphong 37
Chandler 36
Rio de Janeiro 35
Clifton 34
Guangzhou 34
Boston 33
Chicago 30
Buenos Aires 28
Munich 28
Ann Arbor 27
Melbourne 27
Abuja 25
Da Nang 25
Medford 25
Curitiba 22
Mumbai 21
Naples 21
Hải Dương 20
London 20
Shanghai 20
Toronto 20
Guayaquil 19
Montreal 18
Redondo Beach 18
Siena 16
Bari 15
Cotonou 15
Lappeenranta 15
Orem 15
Quito 15
Biên Hòa 14
Brasília 14
Norwalk 14
Salvador 14
Belo Horizonte 13
Bologna 13
Bengaluru 12
Boardman 12
Denver 12
Frankfurt am Main 12
Mexico City 12
Roodt-sur-Syre 12
Turin 12
Turku 12
Brooklyn 11
Ninh Bình 11
Thái Bình 11
Atlanta 10
Campinas 10
Poplar 10
Tianjin 10
Baghdad 9
Falls Church 9
Figino 9
Genoa 9
Lima 9
Palermo 9
Phoenix 9
Shenzhen 9
Amman 8
Totale 9.728
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 305
Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer 225
CD3+ tumor-infiltrating lymphocytes (TILs) as prognostic in patients (pts) with stage II colon cancer (CC) not treated with adjuvant chemotherapy (ADJ) 215
Is there still a place for docetaxel rechallenge in prostate cancer? 210
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 207
Tumor fraction in cell-free DNA as a biomarker in prostate cancer 204
Circulating free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC). 200
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 199
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 196
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 194
A case of eribulin-induced regression of liposarcoma of the left funiculus in a heavily pretreated patient 193
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 189
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry 186
Hyperprogressive disease in advanced cancer patients treated with nivolumab: A case series study 184
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases 183
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 182
Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 180
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer 180
Bone Metastases in Renal Cell Carcinoma: Impact of Immunotherapy on Survival 177
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 177
Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy 177
1204PGOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 171
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) 168
Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine 167
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 167
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 166
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 164
Clinical outcomes of abiraterone acetate (AA) or enzalutamide (E) as first-line therapy (Rx) for men aged ≥75 with metastatic castration-resistant prostate cancer (mCRPC) according to previous use of docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC) in a multicenter international registry: A SPARTACUSS – Meet-URO 26 study 163
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 163
Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials 161
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 160
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 158
Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer 155
Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer 155
Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2 155
Sex and adverse events of adjuvant chemotherapy in colon cancer: an analysis of 34,640 patients in the ACCENT database 155
Prostate cancer: Developing novel approaches to castration-sensitive disease 155
Feasibility of modified docetaxel, oxaliplatin, capecitabine followed by capecitabine as maintenance chemotherapy as first-line therapy for patients with metastatic gastric or gastroesophageal cancer 154
Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis 154
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 154
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer 153
Extramammary invasive Paget’s disease and apocrine angiomatous hamartoma: an unusual association 153
Manuale di oncologia medica 152
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 151
Association of concomitant bone resorption inhibitors with overall survival among patients with metastatic castration-resistant prostate cancer and bone metastases receiving abiraterone acetate with prednisone as first-line therapy. 150
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study 149
Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC) 149
The third line of treatment for metastatic prostate cancer patients: Option or strategy? 148
Hypoxia-Inducible Factor in Renal Cell Carcinoma: From Molecular Insights to Targeted Therapies 148
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience 147
Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer 145
Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. 145
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases 144
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma 143
The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study. 143
Targeted Therapies for Prostate Cancer 141
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 138
Relevance of Gender In the Drug-utilization pattern of Non Small Cell Lung Cancer patients at University Hospital of Siena, Italy (UHS). 135
Cell-Free DNA: Unveiling the Future of Cancer Diagnostics and Monitoring 135
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 134
Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer 133
Impact of Different Selection Approaches for Identifying Lynch Syndrome-Related Colorectal Cancer Patients: Unity Is Strength 130
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience 129
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer 129
Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study 128
Genomic analysis of circulating tumor DNA identifies recurrent molecular features with clinical significance in advanced prostate cancer. 126
Specific clonal expansion at disease progression (PD) in solid cancers pinpointed by cell free DNA analysis. 125
Efficacy of bone resorption inhibitors (BRI) plus abiraterone acetate plus prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry 125
How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue 120
Time for a revision on the role of PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatment for patients with metastatic hormone-refractory prostate cancer 118
No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide 116
Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy 115
Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database 114
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review 114
Outcomes of Prechemotherapy (preCRx) Abiraterone Acetate (AA) or Enzalutamide (E) for Metastatic Castration-Resistant Prostate Cancer (mCRPC) after ADT + Docetaxel (D) or ADT Alone for Metastatic Hormone Sensitive Prostate Cancer (mHSPC) in a Multi-Institution Hospital-based Registry. 113
PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials 109
The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer 108
Using Linked Administrative And Pathology Database To Describe Treatment Patterns Of Non-small-cell Lung Cancer Patients At The Azienda Ospedaliera Universitaria Senese 107
FOLFOX-4 Stop and Go and Capecitabine Maintenance Chemotherapy in the Treatment of Metastatic Colorectal Cancer 106
Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) plus docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry 105
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS-Meet-URO 26 Real-World Study 104
Prior therapy and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based database 99
Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT) 99
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 97
Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel 96
Androgen Blockade and Salvage ­Radiation Therapy in Prostate Cancer: Cautious Optimism Amid Unanswered Questions 95
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry 94
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer 92
Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids 91
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin 91
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study 91
Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab 90
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial) 89
GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis 89
Oral Metronomic Chemo-Hormonal-Therapy of Metastatic Breast Cancer with Cyclophosphamide and Megestrol Acetate 87
Reduced Dose of Abiraterone Acetate with Concomitant Low-dose Prednisone in the Treatment of ≥ 85 Year-old Patients with Advanced Castrate-resistant Prostate Cancer 85
Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors 84
Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin 81
Weekly high‐dose calcitriol and docetaxel in patients with metastatic hormone‐refractory prostate cancer previously exposed to docetaxel 77
Efficacy and safety analysis of once per cycle pegfilgrastim and daily lenograstim in patients with breast cancer receiving adjuvant myelosuppressive chemotherapy FEC 100: a pilot study 76
Totale 14.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.606
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.606
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022363 5 5 21 24 4 41 45 22 15 17 63 101
2022/2023631 77 203 37 34 4 116 95 8 43 0 8 6
2023/2024519 8 18 53 48 78 97 10 69 21 46 42 29
2024/20253.998 130 265 156 411 1.314 1.054 68 96 105 73 119 207
2025/20267.045 369 1.034 1.067 1.304 582 194 631 319 319 317 271 638
2026/2027273 273 0 0 0 0 0 0 0 0 0 0 0
Totale 14.575